ALX Oncology Holdings Inc.

NASDAQ:ALXO

1.83 (USD) • At close December 24, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

202320222021202020192018
Revenue 0001.1824.7962.067
Cost of Revenue 0.8361.4660.7361.0754.361.88
Gross Profit -0.836-1.466-0.7360.1070.4360.187
Gross Profit Ratio 0000.0910.0910.09
Reseach & Development Expenses 141.79598.460.1728.96116.30611.27
General & Administrative Expenses 28.48329.03623.38514.8093.3132.601
Selling & Marketing Expenses 000000
SG&A 28.48329.03623.38514.8093.3132.601
Other Expenses 0-0.260.084-0.404-0.005-0.002
Operating Expenses 170.278127.43683.55543.7719.61913.871
Operating Income -170.278-127.436-83.555-43.663-19.183-13.684
Operating Income Ratio 000-36.94-4-6.62
Total Other Income Expenses Net 9.4734.0180.071-1.836-0.026-0.002
Income Before Tax -160.805-123.418-83.484-45.499-19.209-13.686
Income Before Tax Ratio 000-38.493-4.005-6.621
Income Tax Expense 00.064-0.0210.2410.0340.045
Net Income -160.805-123.482-83.463-45.74-19.243-13.731
Net Income Ratio 000-38.697-4.012-6.643
EPS -3.74-3.03-2.07-1.15-0.53-0.63
EPS Diluted -3.74-3.03-2.07-1.15-0.53-0.63
EBITDA -158.404-121.952-83.471-43.461-18.759-13.255
EBITDA Ratio 000-37.282-3.911-6.413